Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
Neuroscientists are venturing into new areas positing that through attentive thinking (meditating) we can reshape the hard drive of our brains.
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
UK issues ban on second SSRI antidepressant for children Sun, 21 Sep 2003 The UK Observer reports (below) that although antidepressant drugs of the SSRI class have not been approved for children, last year doctors (who are unaware of the severe risks associated with SSRIs) wrote 170,000 prescriptions of antidepressants…
GlascoSmithKline PAXIL Warning letter to Healthcare Professionals Thu, 19 Jun 2003 On June 10 the British government disapproved a license the widely popular, SSRI antidepressant, Seroxat (PAXIL), for use in children and adolescents after a committee examined the data from 9 clinical trials. The British Medicine and Healthcare Products Regulatory…
AHRP Campaign to Protect Children from Harm Oct 15: FDA Orders Black Box Warnings on Antidepressants labels and Patient Information Guides to Warn about Suicide risk Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sep 30: GSK Sales Reps told NOT to Divulge Paxill Data…
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…